Research programme: peptide therapeutics - Animate Biosciences
Latest Information Update: 13 Oct 2026
At a glance
- Originator Animate Biosciences
- Class Anti-inflammatories; Antifibrotics; Cardiovascular therapies; Hepatoprotectants; Peptides; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lung disorders; Skin disorders
- Research Cardiovascular disorders; Liver disorders
- Discontinued Fibrosis; Inflammation
Most Recent Events
- 13 Oct 2026 Discontinued - Preclinical for Fibrosis in USA (unspecified route) (Animate Biosciences pipeline, September 2026)
- 13 Oct 2026 Discontinued - Preclinical for Inflammation in USA (unspecified route) (Animate Biosciences pipeline, September 2026)
- 23 Sep 2026 Early research in Cardiovascular disorders in USA (Unspecified), prior to September 2026 (Animate Biosciences pipeline, September 2026)